Glioma Quiz

Quiz

Safusidenib Erbumine for IDH1-Mutated Glioma

03/03/2026

Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.

Test your knowledge on...

03/03/2026

Oncology

Quiz

Evaluating Targeted Therapies in Glioblastoma

01/26/2026

True or false: Targeted therapies—including immune checkpoint inhibitors (ICIs) and mammalian target of rapamycin (mTOR) inhibitors—did not demonstrate improved survival in unselected glioblastoma populations, according to a systematic review...

True or false: Targeted...

01/26/2026

Oncology

Quiz

Eflornithine Plus Lomustine for Recurrent Grade 3 Astrocytoma

01/13/2026

True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...

True or false: Eflornithine...

01/13/2026

Oncology

Quiz

Vorasidenib for Previously Untreated Patients With Residual or Recurrent Grade 2 IDH-Mutant Glioma

08/19/2025

The phase 3 INDIGO trial enrolled previously untreated patients with residual or recurrent grade 2 IDH-mutant glioma to receive either vorasidenib or placebo. Which of the following statements best summarizes the primary clinical outcome of...

The phase 3 INDIGO trial...

08/19/2025

Oncology

Quiz

Concurrent Temozolomide and Radiotherapy for Patients With Non-Codeleted Anaplastic Glioma

07/28/2025

True or False: Concurrent temozolomide and radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients with non-codeleted anaplastic glioma.

True or False: Concurrent...

07/28/2025

Oncology

Recent News

FDA Approval

FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma

03/20/2026

Emily Estrada

Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.

Based on results from the SWOG...

03/20/2026

Oncology

News

Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer

03/18/2026

Emily Estrada

According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.

According to a comparative...

03/18/2026

Oncology

News

Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma

03/11/2026

Stephanie Holland

Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...

Interim results from the phase 3...

03/11/2026

Oncology

News

Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma

03/11/2026

Stephanie Holland

Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.

Interim results from the phase 3...

03/11/2026

Oncology

News

FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer

03/11/2026

Stephanie Holland

Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.

Based on results from the OSPREY...

03/11/2026

Radiopharmaceutical Education Institute

FDA Alerts

Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial

03/11/2026

Stephanie Holland

Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.

Based on emerging safety data...

03/11/2026

Oncology

News

Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor

03/11/2026

Stephanie Holland

Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.

Updated safety results from the...

03/11/2026

Oncology

News

Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma

03/05/2026

Stephanie Holland

Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.

Results from the phase 3 C-POST...

03/05/2026

Oncology

FDA Approval

FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma

03/05/2026

Emily Estrada

Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.

Based on results from the phase...

03/05/2026

Oncology

News

Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer

03/04/2026

Emily Estrada

Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.

Results from the SWOG S162 study...

03/04/2026

Oncology